Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314

References

• Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63:803 - 43; http://dx.doi.org/10.2165/00003495-200363080-00005; PMID: 12662126
   PubMed Web of Science ®Google Scholar
• Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18:3135 - 43; PMID: 10963642
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005; 353:1734 - 6; http://dx.doi.org/10.1056/NEJMe058196; PMID: 16236745
   PubMed Web of Science ®Google Scholar
• Collins TS, Hurwitz HI. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Semin Oncol 2005; 32:61 - 8; http://dx.doi.org/10.1053/j.seminoncol.2004.09.026; PMID: 15726507
   PubMed Web of Science ®Google Scholar
• Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, et al. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol 2006; 43:1183 - 93; http://dx.doi.org/10.1016/j.molimm.2005.07.010; PMID: 16102830
   PubMed Web of Science ®Google Scholar
• van der Kolk LE, Grillo-López AJ, Baars JW, Hack CE, van Oers MHJ. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001; 115:807 - 11; http://dx.doi.org/10.1046/j.1365-2141.2001.03166.x; PMID: 11843813
   PubMed Web of Science ®Google Scholar
• Tawara T, Hasegawa K, Sugiura Y, Harada K, Miura T, Hayashi S, et al. Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats. J Immunol 2008; 180:2294 - 8; PMID: 18250438
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754 - 8; http://dx.doi.org/10.1182/blood.V99.3.754; PMID: 11806974
   PubMed Web of Science ®Google Scholar
• Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AEGK, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90:1109 - 14; PMID: 9242542
   PubMed Web of Science ®Google Scholar
• Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276:6591 - 604; http://dx.doi.org/10.1074/jbc.M009483200; PMID: 11096108
   PubMed Web of Science ®Google Scholar
• Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol 2004; 336:1239 - 49; http://dx.doi.org/10.1016/j.jmb.2004.01.007; PMID: 15037082
   PubMed Web of Science ®Google Scholar
• Shields RL, Lai J, Keck R, O’Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733 - 40; http://dx.doi.org/10.1074/jbc.M202069200; PMID: 11986321
   PubMed Web of Science ®Google Scholar
• Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism. Clin Cancer Res 2004; 10:6248 - 55; http://dx.doi.org/10.1158/1078-0432.CCR-04-0850; PMID: 15448014
   PubMed Web of Science ®Google Scholar
• Ferrara C, Stuart F, Sondermann P, Brünker P, Umaña P. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 2006; 281:5032 - 6; http://dx.doi.org/10.1074/jbc.M510171200; PMID: 16330541
   PubMed Web of Science ®Google Scholar
• Satoh M, Iida S, Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 2006; 6:1161 - 73; http://dx.doi.org/10.1517/14712598.6.11.1161; PMID: 17049014
   PubMed Web of Science ®Google Scholar
• Jefferis R, Lund J, Pound JD. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol Rev 1998; 163:59 - 76; http://dx.doi.org/10.1111/j.1600-065X.1998.tb01188.x; PMID: 9700502
   PubMed Web of Science ®Google Scholar
• Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng 2001; 74:288 - 94; http://dx.doi.org/10.1002/bit.1119; PMID: 11410853
   PubMed Web of Science ®Google Scholar
• Cox KM, Sterling JD, Regan JT, Gasdaska JR, Frantz KK, Peele CG, et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol 2006; 24:1591 - 7; http://dx.doi.org/10.1038/nbt1260; PMID: 17128273
   PubMed Web of Science ®Google Scholar
• Schuster M, Umana P, Ferrara C, Brünker P, Gerdes C, Waxenecker G, et al. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res 2005; 65:7934 - 41; PMID: 16140965
   PubMed Web of Science ®Google Scholar
• Hodoniczky J, Zheng YZ, James DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 2005; 21:1644 - 52; http://dx.doi.org/10.1021/bp050228w; PMID: 16321047
   PubMed Web of Science ®Google Scholar
• Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104:2635 - 42; http://dx.doi.org/10.1182/blood-2004-03-1110; PMID: 15226177
   PubMed Web of Science ®Google Scholar
• Dettke M, Loibner H. Different types of FCgamma-receptors are involved in anti-Lewis Y antibody induced effector functions in vitro. Br J Cancer 2000; 82:441 - 5; PMID: 10646902
   PubMed Web of Science ®Google Scholar
• Marsh CB, Gadek JE, Kindt GC, Moore SA, Wewers MD. Monocyte Fc gamma receptor cross-linking induces IL-8 production. J Immunol 1995; 155:3161 - 7; PMID: 7673729
   PubMed Web of Science ®Google Scholar
• Deo YM, Graziano RF, Repp R, van de Winkel JG. Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. Immunol Today 1997; 18:127 - 35; http://dx.doi.org/10.1016/S0167-5699(97)01007-4; PMID: 9078685
   PubMedGoogle Scholar
• Debets JM, Van de Winkel JG, Ceuppens JL, Dieteren IE, Buurman WA. Cross-linking of both Fc gamma RI and Fc gamma RII induces secretion of tumor necrosis factor by human monocytes, requiring high affinity Fc-Fc gamma R interactions. Functional activation of Fc gamma RII by treatment with proteases or neuraminidase. J Immunol 1990; 144:1304 - 10; PMID: 2137489
   PubMed Web of Science ®Google Scholar
• Nechansky A, Schuster M, Jost W, Siegl P, Wiederkum S, Gorr G, et al. Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies. Mol Immunol 2007; 44:1815 - 7; http://dx.doi.org/10.1016/j.molimm.2006.08.013; PMID: 17011625
   PubMed Web of Science ®Google Scholar
• Schuster M, Jost W, Mudde GC, Wiederkum S, Schwager C, Janzek E, et al. In vivo glyco-engineered antibody with improved lytic potential produced by an innovative non-mammalian expression system. Biotechnol J 2007; 2:700 - 8; http://dx.doi.org/10.1002/biot.200600255; PMID: 17427997
   PubMedGoogle Scholar
• Kim YS, Yuan M, Itzkowitz SH, Sun QB, Kaizu T, Palekar A, et al. Expression of LeY and extended LeY blood group-related antigens in human malignant, premalignant, and nonmalignant colonic tissues. Cancer Res 1986; 46:5985 - 92; PMID: 2428490
   PubMed Web of Science ®Google Scholar
• Miyake M, Taki T, Hitomi S, Hakomori S. Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. N Engl J Med 1992; 327:14 - 8; http://dx.doi.org/10.1056/NEJM199207023270103; PMID: 1317941
   PubMed Web of Science ®Google Scholar
• Steplewska-Mazur K, Gabriel A, Zajecki W, Wylezoł M, Glück M. Breast cancer progression and expression of blood group-related tumor-associated antigens. Hybridoma 2000; 19:129 - 33; http://dx.doi.org/10.1089/02724570050031167; PMID: 10868792
   PubMed Web of Science ®Google Scholar
• Inufusa H, Nakatani Y, Adachi T, Wakano T, Nakajima A, Nakamura M, et al. Correlation of prognosis of breast cancer patients and expression of Ley which acts as a cofactor of tumor procoagulant. Int J Oncol 1998; 13:481 - 7; PMID: 9683782
   PubMed Web of Science ®Google Scholar
• Madjd Z, Parsons T, Watson NF, Spendlove I, Ellis I, Durrant LG. High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. Breast Cancer Res 2005; 7:R780 - 7; http://dx.doi.org/10.1186/bcr1305; PMID: 16168124
   PubMed Web of Science ®Google Scholar
• Ishida T, Ishii T, Inagaki A, Yano H, Kusumoto S, Ri M, et al. The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma. Leukemia 2006; 20:2162 - 8; http://dx.doi.org/10.1038/sj.leu.2404415; PMID: 17039235
   PubMed Web of Science ®Google Scholar
• Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 2007; 96:41 - 101; http://dx.doi.org/10.1016/S0065-2776(07)96002-2; PMID: 17981204
   PubMed Web of Science ®Google Scholar
• Oruzio DV, Waxenecker G, Aulmann C, Märkl B, Wagner T, Mudde GC, et al.. Phase I dose escalation study with Le Y carbohydrate specific humanized mAb IGN311. J Cancer Therapy 2011; (2):760-71.
   Google Scholar
• Farhan H, Schuster C, Klinger M, Weisz E, Waxenecker G, Schuster M, et al. Inhibition of xenograft tumor growth and down-regulation of ErbB receptors by an antibody directed against Lewis Y antigen. J Pharmacol Exp Ther 2006; 319:1459 - 66; http://dx.doi.org/10.1124/jpet.106.107318; PMID: 16963623
   PubMed Web of Science ®Google Scholar
• Klinger M, Farhan H, Just H, Drobny H, Himmler G, Loibner H, et al. Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors. Cancer Res 2004; 64:1087 - 93; http://dx.doi.org/10.1158/0008-5472.CAN-03-2435; PMID: 14871842
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278:3466 - 73; http://dx.doi.org/10.1074/jbc.M210665200; PMID: 12427744
   PubMed Web of Science ®Google Scholar
• Brodzik R, Glogowska M, Bandurska K, Okulicz M, Deka D, Ko K, et al. Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells. Proc Natl Acad Sci U S A 2006; 103:8804 - 9; http://dx.doi.org/10.1073/pnas.0603043103; PMID: 16720700
   PubMed Web of Science ®Google Scholar
• Wing MG, Moreau T, Greenwood J, Smith RM, Hale G, Isaacs J, et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 1996; 98:2819 - 26; http://dx.doi.org/10.1172/JCI119110; PMID: 8981930
   PubMed Web of Science ®Google Scholar
• Tax WJ, Tamboer WP, Jacobs CW, Frenken LA, Koene RA. Role of polymorphic Fc receptor Fc gammaRIIa in cytokine release and adverse effects of murine IgG1 anti-CD3/T cell receptor antibody (WT31). Transplantation 1997; 63:106 - 12; http://dx.doi.org/10.1097/00007890-199701150-00020; PMID: 9000670
   PubMed Web of Science ®Google Scholar
• Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94:2217 - 24; PMID: 10498591
   PubMed Web of Science ®Google Scholar
• Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 13:399 - 415; http://dx.doi.org/10.1146/annurev.iy.13.040195.002151; PMID: 7612229
   PubMed Web of Science ®Google Scholar
• Boyd PN, Lines AC, Patel AK. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 1995; 32:1311 - 8; http://dx.doi.org/10.1016/0161-5890(95)00118-2; PMID: 8643100
   PubMed Web of Science ®Google Scholar
• Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20:471 - 8; http://dx.doi.org/10.1016/j.coi.2008.06.007; PMID: 18606225
   PubMed Web of Science ®Google Scholar
• Nechansky A, Szolar OH, Siegl P, Zinoecker I, Halanek N, Wiederkum S, et al. Complement dependent cytotoxicity (CDC) activity of a humanized anti Lewis-Y antibody: FACS-based assay versus the ‘classical’ radioactive method -- qualification, comparison and application of the FACS-based approach. J Pharm Biomed Anal 2009; 49:1014 - 20; http://dx.doi.org/10.1016/j.jpba.2009.01.029; PMID: 19250790
   PubMed Web of Science ®Google Scholar
• Co MS, Baker J, Bednarik K, Janzek E, Neruda W, Mayer P, et al. Humanized anti-Lewis Y antibodies: in vitro properties and pharmacokinetics in rhesus monkeys. Cancer Res 1996; 56:1118 - 25; PMID: 8640770
   PubMed Web of Science ®Google Scholar
• Kircheis R, Siegl P, Grunt S, Halanek N, Loibner H, Mudde GC, et al. Immunization of Rhesus monkeys with a SialylTn-mAb17-1A conjugate vaccine co-formulated with QS-21 induces a temporary systemic cytokine release and NK cytotoxicity against tumor cells. Cancer Immunol Immunother 2007; 56:863 - 73; http://dx.doi.org/10.1007/s00262-006-0231-x; PMID: 17009044
   PubMed Web of Science ®Google Scholar